Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing antibody complement therapeutics for severe autoimmune diseases, has announced its upcoming participation in two major investor conferences in February 2025.

The company's CEO, Marino Garcia, will present at the Guggenheim SMID Cap Biotech Conference on February 6 at 9:00 a.m. ET in New York City, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 p.m. ET, which will be held virtually.

Interested parties can access live webcasts of both presentations through the 'News and Events' section of the Investors page on Dianthus Therapeutics' website.

News Market Reaction

+4.36%

1 alert

+4.36% News Effect

On the day this news was published, DNTH gained 4.36%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:

• Guggenheim SMID Cap Biotech Conference – Fireside chat on February 6 at 9:00 a.m. ET in New York City
• Oppenheimer 35th Annual Healthcare Life Sciences Conference – Fireside chat on February 12 at 3:20 p.m. ET, taking place virtually

Live webcasts of the Company’s presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

When and where will Dianthus Therapeutics (DNTH) present at the Guggenheim SMID Cap Biotech Conference?

Dianthus Therapeutics will present at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 9:00 a.m. ET in New York City.

What time is Dianthus Therapeutics' (DNTH) presentation at the Oppenheimer Healthcare Conference?

Dianthus Therapeutics will present at the Oppenheimer Healthcare Life Sciences Conference on February 12, 2025, at 3:20 p.m. ET virtually.

How can investors access Dianthus Therapeutics' (DNTH) February 2025 conference presentations?

Investors can access live webcasts of the presentations through the 'News and Events' section in the Investors area of the Dianthus Therapeutics website.

Which investor conferences will Dianthus Therapeutics (DNTH) attend in February 2025?

Dianthus Therapeutics will attend the Guggenheim SMID Cap Biotech Conference and the Oppenheimer 35th Annual Healthcare Life Sciences Conference in February 2025.